throbber
08-CV-1512-MMA
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE SOUTHERN DISTRICT OF CALIFORNIA
`HONORABLE MICHAEL M. ANELLO, DISTRICT JUDGE
`MEDTRONIC SOFAMOR DANEK, USA, .
`ET AL., .CASE NO. 08-CV-1512-MMA
`.
`PLAINTIFF,
`.
`.
`V.
`. AUGUST 31, 2011
`.
`NUVASIVE, INC.,
`. WEDNESDAY, 1:30 P.M.
`.
`DEFENDANT.
`. TRIAL - DAY TWO
`. . . . . . . . . . . . . . . . . ..
`
`REPORTER'S TRANSCRIPT OF PROCEEDINGS
`
`APPEARANCES:
`FOR THE PLAINTIFF:
`
`FOR THE DEFENDANTS:
`
`LUKE L. DAUCHOT, ESQ.
`NIMALKA WICKRAMASEKERA, ESQ.
`SHARRE LOTFOLLAHI, ESQ.
`ALEXANDER F. MACKINNON, ESQ.
`MICHAEL DOBSZEWICZ, ESQ.
`KIRKLAND & ELLIS, LLP
`JEFF SCHWARTZ, ESQ.
`DEWEY & LEBOEUF
`
`FRANK SCHERKENBACH, ESQ.
`JOHN M. FARRELL, ESQ.
`TODD G. MILLER, ESQ.
`JONATHAN J. LAMBERSON, ESQ.
`NEIL WARREN, ESQ.
`KEELEY I. VEGA, ESQ.
`
`COURT REPORTER:
`
`JULIET Y. EICHENLAUB, CSR
`USDC CLERK'S OFFICE
`880 FRONT STREET, ROOM 4290
`SAN DIEGO, CALIFORNIA 92101
`JULIET_EICHENLAUB@CASD.USCOURTS.GOV
`REPORTED BY STENOTYPE, TRANSCRIBED BY COMPUTER
`
`310
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` 1
`
`NUVASIVE 1045
`NuVasive, Inc. v. Warsaw Orthopedic, Inc.
`IPR2013-00206
`IPR2013-00208
`
`

`
`08-CV-1512-MMA
`
`ANSWER: YES.
`QUESTION: WHAT DID YOU THINK?
`ANSWER: I THOUGHT IT WAS AN INTERESTING START. THE
`NOTION OF TRYING TO NOT ONLY STIMULATE A NERVE BUT MONITOR
`THE LOCATION OF THAT NERVE OR THE PROXIMITY OF THAT NERVE
`WAS ONE OF THE GOALS OF NUVASIVE'S WORK, AS LEAST AS FAR
`AS I WAS INVOLVED IN IT. AND THIS WAS -- THIS WAS VERY
`EARLY WORK, BUT IT WAS HEADED IN THAT DIRECTION."
`MS. WICKRAMASEKERA: AND THAT'S THE END OF THE
`TRANSCRIPT, YOUR HONOR.
`THE COURT: ALL RIGHT. THANK YOU, DR. FOLEY. YOU
`DID A VERY GOOD JOB.
`THE WITNESS: THANK YOU.
`MS. WICKRAMASEKERA: I'D JUST LIKE TO ADD THAT DURING
`THESE VIDEO CLIPS, WE SAW THE FOLLOWING EXHIBITS: PX305,
`PX2490, PX2491, PX2493, AND PX2492.
`THE COURT: ALL RIGHT.
`MS. WICKRAMASEKERA: THANK YOU.
`THE COURT: NEXT WITNESS.
`MR. DAUCHOT: YOUR HONOR, FOR OUR NEXT WITNESS, WE
`CALL MR. PATRICK MILES.
`PATRICK MILES, PLAINTIFF'S WITNESS, TESTIFIED AS FOLLWS:
`THE CLERK: PLEASE RAISE YOUR RIGHT HAND. DO YOU
`SOLEMNLY SWEAR THAT THE TESTIMONY YOU SHALL GIVE IN THE CAUSE
`NOW BEFORE THE COURT IS THE TRUTH, THE WHOLE TRUTH, AND NOTHING
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`400
`
` 2
`
`

`
`08-CV-1512-MMA
`
`BUT THE TRUTH, SO HELP YOU GOD?
`THE WITNESS: I DO.
`THE CLERK: PLEASE STATE YOUR FULL NAME FOR THE
`RECORD AND SPELL IT PLEASE.
`THE WITNESS: PATRICK MILES. LAST NAME, M-I-L-E-S.
`FIRST NAME, P-A-T-R-I-C-K.
`THE COURT: THANKS, MR. MILES. GO AHEAD AND HAVE A
`SEAT. MR. DAUCHOT?
`
`DIRECT EXAMINATION
`
`BY MR. DAUCHOT:
`Q.
`THANK YOU, YOUR HONOR.
`MR. MILES, GOOD AFTERNOON.
`GOOD AFTERNOON.
`THIS IS THE FIRST TIME WE MET?
`FIRST TIME YOU AND I MET?
`YES.
`I BELIEVE SO.
`YOU'VE BEEN DEPOSED IN THIS CASE BEFORE, THOUGH?
`I HAVE.
`I THINK MY COLLEAGUE, MS. WICKRAMASEKERA, DID THAT.
`DO YOU REMEMBER THAT?
`I DO.
`YOU BEGAN WORKING FOR NUVASIVE IN JANUARY 2001; AM I
`
`A.
`Q.
`A.
`Q.
`A.
`Q.
`A.
`Q.
`
`A.
`Q.
`RIGHT?
`A.
`
`YES.
`
`401
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` 3
`
`

`
`08-CV-1512-MMA
`
`AND YOU -- THAT'S WHEN MR. VALENTINE ALSO JOINED THE
`Q.
`COMPANY; CORRECT?
`A.
`IT IS.
`Q.
`AND YOU LEFT MEDTRONIC SOFAMOR DANEK IN APRIL OF
`2000; IS THAT ABOUT RIGHT?
`A.
`I BELIEVE SO; YEAH, LEFT MEDTRONIC.
`Q.
`AND WHEN YOU LEFT MEDTRONIC SOFAMOR DANEK, YOUR
`PRINCIPAL AREA OF WORK WAS WHAT WE CALL MINIMALLY INVASIVE
`SPINE SURGERY DEVICES; AM I RIGHT?
`A.
`YES; IT WAS THAT AND CERVICAL SPINE SURGERY.
`Q.
`AND WHEN YOU WORKED ON MINIMALLY INVASIVE SPINE
`SURGERY DEVICES FOR SOFAMOR DANEK, YOU DID SO WITH DR. FOLEY;
`AM I CORRECT?
`A.
`YES, I DID.
`Q.
`AND YOU ALSO WORKED WITH MR. MELKENT; AM I RIGHT?
`A.
`NOT DIRECTLY.
`Q.
`INDIRECTLY?
`A.
`INDIRECTLY, YES.
`Q.
`INDIRECTLY. ALL RIGHT.
`AND YOU ALSO WORKED WITH MR. BOYD?
`NOT COMMONLY.
`A.
`UNCOMMONLY?
`Q.
`IF THAT'S THE WAY YOU'D LIKE TO CHARACTERIZE IT. I
`A.
`DIDN'T SEE HIM VERY OFTEN.
`Q.
`OKAY.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`402
`
` 4
`
`

`
`08-CV-1512-MMA
`
`BUT YOU DID WORK WITH HIM FROM TIME TO TIME?
`HE WAS WITH THE SAME COMPANY, YES. I DON'T RECALL,
`A.
`FROM TIME TO TIME.
`Q.
`AND MR. BOYD IS NOW A CONSULTANT TO NUVASIVE?
`A.
`YES.
`Q.
`ALL RIGHT.
`NOW, NUVASIVE COMMERCIALLY LAUNCHED XLIF IN OCTOBER
`2003; AM I RIGHT?
`A.
`YES.
`Q.
`AND I TAKE IT THAT YOU WERE INVOLVED IN THAT RELEASE,
`THAT PUBLIC LAUNCH?
`A.
`UH-HUH, YES, I WAS.
`Q.
`AND I ASSUME YOU DID THAT WHEN YOU FELT THAT THE
`ENTIRE XLIF SYSTEM WAS READY TO LAUNCH FOR THE PUBLIC; FAIR
`STATEMENT?
`A.
`WE LAUNCHED IT WHEN WE FELT IT WAS A SAFE AND
`REPRODUCIBLE PROCEDURE.
`Q.
`YOU LAUNCHED IT WHEN YOU THOUGHT IT WAS SAFE AND WHEN
`YOU THOUGHT IT WAS REPRODUCIBLE, RIGHT?
`A.
`YES.
`Q.
`NOW, YOUR POSITION IS THAT NEUROVISION WAS KEY TO
`THAT; AM I RIGHT?
`A.
`YES.
`Q.
`ALL RIGHT.
`NOW, DO YOU RECALL -- WELL, LET'S TAKE A STEP BACK.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`403
`
` 5
`
`

`
`08-CV-1512-MMA
`
`A.
`Q.
`
`CAN YOU SEE THAT OKAY?
`I CAN.
`OKAY.
`SO YOU LAUNCH XLIF, AND XLIF STANDS FOR EXTREME
`LATERAL INTERBODY FUSION?
`A.
`THAT'S CORRECT.
`Q.
`IN OCTOBER OF 2003; CORRECT?
`A.
`YES, SIR.
`Q.
`AND YOU LAUNCHED IT THEN BECAUSE AT THAT POINT IN
`TIME THE SYSTEM, XLIF, WAS, AS YOU PUT IT, SAFE TO DO AND
`REPRODUCIBLE, RIGHT?
`A.
`YES.
`Q.
`NOW, THAT'S OCTOBER 2003.
`LET'S GO BACK IN TIME; OKAY. AND LET'S GET US TO
`NOVEMBER OF 2001. I ASSUME THAT SINCE YOU HADN'T LAUNCHED XLIF
`YET THAT AT THIS TIME IT WASN'T SAFE AND REPRODUCIBLE;
`CORRECT?
`IT WAS -- IT HADN'T COME UP. I GUESS I DON'T
`A.
`UNDERSTAND YOUR QUESTION.
`Q.
`MY QUESTION IS: YOU LAUNCHED IT IN OCTOBER 2003
`BECAUSE XLIF WAS, I THINK YOU SAID, READY; IN THAT SENSE, YOU
`MEANT SAFE AND REPRODUCIBLE?
`A.
`YES. WE WENT THROUGH THE ENTIRE DESIGN PROCESS, AND
`WE HAD NEVER CONTEMPLATE IT IN NOVEMBER 2001.
`Q.
`YOU NEVER CONTEMPLATE IT IN 2001?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`404
`
` 6
`
`

`
`08-CV-1512-MMA
`
`NOT WHAT WAS RELEASED IN 2003.
`A.
`NOW, WHAT I'D LIKE YOU TO TURN TO IS PX2541. IT'S A
`Q.
`RELEASE, A PRESS RELEASE, FROM NUVASIVE, DATED NOVEMBER 27TH,
`2001. DAVE, CAN YOU PUT THAT UP FOR US? CAN YOU PUT THAT UP
`FOR US?
`
`ALL RIGHT. AND CAN YOU BLOW UP THE BOTTOM, THE
`SECOND PARAGRAPH FROM THE BOTTOM.
`THIS IS A DOCUMENT DATED NOVEMBER 2001; CORRECT,
`MR. MILES?
`A.
`IT APPEARS AS SUCH.
`Q.
`IT'S A PRESS RELEASE FROM NUVASIVE; AM I CORRECT,
`MR. MILES?
`A.
`IT APPEARS SO, YES.
`Q.
`WE ARE NOW AT NOVEMBER 27, 2001. "THE MINIMALLY
`INVASIVE XLIF, STANDING FOR EXTREME LATERAL INTERBODY FUSION
`APPROACH TO THE SPINE DEVELOPED BY NUVASIVE IS MADE POSSIBLE
`THROUGH ACTIVE NERVE MONITORING OFFERED BY THE NEUROVISION
`SYSTEM."
`
`DO YOU SEE THAT?
`YES, I DO.
`A.
`SO YOU IN FACT DID HAVE -- YOU WERE TELLING THE
`Q.
`PUBLIC IN NOVEMBER 2001 THAT YOU DID HAVE XLIF?
`A.
`UNDER THE AUSPICES OF XLIF 60; IT WAS A DIFFERENT
`PROCEDURE THAN WHAT WAS, THAN WHAT WAS LAUNCHED IN OCTOBER OF
`2003.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`405
`
` 7
`
`

`
`08-CV-1512-MMA
`
`IT WAS A DIFFERENT XLIF?
`Q.
`THAT'S CORRECT.
`A.
`SO YOU HAD TWO XLIF PROCEDURES AT NUVASIVE?
`Q.
`THAT'S CORRECT.
`A.
`WAS IT XLIF, WHAT, ONE AND XLIF TWO?
`Q.
`NO. IT WAS XLIF 60 AND XLIF 90.
`A.
`IS THERE A DOCUMENT THAT SHOWS US THE XLIF 60 VERSUS
`Q.
`THE XLIF 90 THAT YOU KNOW OF?
`A.
`I'M SURE THERE IS. THERE'S BEEN A BOOK CHAPTER ON
`XLIF 60 AND A BOOK CHAPTER ON XLIF 90.
`Q.
`IT'S A FACT THAT IN 2001 THAT XLIF WAS NOT SAFE AND
`REPRODUCIBLE; CORRECT?
`A.
`IN 2001, XLIF WAS NOT SAFE AND REPRODUCIBLE.
`Q.
`ALL RIGHT. NOW IN NOVEMBER 2001 --
`A.
`LET ME ANSWER THE QUESTION. I WOULD SAY IT DEPENDS
`UPON WHO WAS DOING THE SURGERY.
`Q.
`I SEE.
`NOW, IN NOVEMBER OF 2001, YOU HAD NEUROMONITORING;
`HAD YOU NEUROVISION, RIGHT?
`A.
`THAT'S CORRECT.
`Q.
`AND IN NOVEMBER OF 2001, YOU HAD THE XLIF PROCEDURE
`SURGICAL APPROACH; AM I CORRECT?
`A.
`WE HAD XLIF 60.
`Q.
`XLIF 60.
`NOW, XLIF 60, WAS THAT THE SURGICAL PROCEDURE
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`406
`
` 8
`
`

`
`08-CV-1512-MMA
`
`A.
`Q.
`
`DEVELOPED BY DR. PIMENTA?
`A.
`NO.
`Q.
`ALL RIGHT. WE'LL COME BACK TO THAT.
`BY OCTOBER OF 2003, YOU HAD TWO ADDITIONAL THINGS:
`YOU HAD MORE THAN NEUROVISION, AND YOU HAD MORE THAN THE XLIF
`PROCEDURE; AM I CORRECT?
`A.
`WE HAD MORE COMPONENTS TO THE PROCEDURE AND A
`COMPLETELY DIFFERENT PROCEDURE.
`Q.
`OKAY.
`SO IT WAS A COMPLETELY DIFFERENT PROCEDURE?
`THAT'S CORRECT.
`AND HOW WAS THE PROCEDURE DIFFERENT?
`THERE'S A RULE IN CROSS-EXAMINATION: YOU NEVER ASK A
`QUESTION TO WHICH YOU DON'T KNOW THE ANSWER, AND I DON'T KNOW
`THE ANSWER TO THAT QUESTION. BUT I'LL ASK IT ANYWAY.
`A.
`THERE ARE NUMEROUS DISTINCTIONS IN THE TWO DIFFERENT
`PROCEDURES.
`Q.
`WHAT'S XLIF 60?
`A.
`ONE IS -- XLIF 60 WOULD BE IF YOU'RE LAYING ON YOUR
`BELLY, AND YOU GO OFF OF THE MIDLINE 60 DEGREES, AND YOU
`APPROACH THE SPINE IN THAT MANNER. SO IT WOULD BE MORE OF A
`POSTERIOR-LATERAL APPROACH. THE XLIF 90 WOULD BE IF SOMEONE IS
`LAYING ON THEIR SIDE, AND WHAT YOU DO IS APPROACH IT FROM A
`DIRECT 90-DEGREE APPROACH. SO 90-DEGREE MIDLINE VERSUS
`60-DEGREE MIDLINE. THE REQUIREMENTS FOR THOSE SURGERIES ARE
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`407
`
` 9
`
`

`
`08-CV-1512-MMA
`
`COMPLETELY DIFFERENT.
`Q.
`ALL RIGHT.
`YOU'RE SAYING THIS WAS A PROCEDURE -- XLIF 60 WAS NOT
`DEVELOPED BY DR. PIMENTA?
`A.
`THAT'S CORRECT.
`Q.
`AND XLIF 90, WAS THAT DEVELOPED BY DR. PIMENTA?
`A.
`YES, IT WAS.
`Q.
`AS OF NOVEMBER 2001, YOU DID NOT HAVE XLIF 60
`DEVELOPED BY DR. PIMENTA; OR YOU HAD XLIF 60, BUT IT WAS NOT
`DEVELOPED BY DR. PIMENTA?
`A.
`THAT'S CORRECT.
`Q.
`NOW, CAN WE PUT UP, CHRIS, THE TEXTBOOK?
`LET ME JUST MAKE CLEAR SO WE ALL UNDERSTAND. XLIF
`60, NO DR. PIMENTA, RIGHT; AND XLIF 90, DR. PIMENTA; AM I
`RIGHT?
`A.
`Q.
`SIR?
`PX WHAT?
`A.
`44, THE TEXTBOOK?
`Q.
`YES.
`A.
`AND THAT IS -- OKAY. PX 44. WHAT I'D LIKE TO DO IS
`Q.
`TURN TO, AND FLIP IN A COUPLE PAGES TO THE ACKNOWLEDGEMENT.
`YOU SEE ACKNOWLEDGEMENTS. CAN YOU BLOW THAT UP FOR US, DAVID,
`PLEASE? WE ARE ON PAGE -- IT'S THE PREFACE -- ROMAN NUMERAL
`
`YES.
`NOW, I WANT TO -- DO YOU HAVE PX44 IN FRONT OF YOU,
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`408
`
`
`10
`
`

`
`08-CV-1512-MMA
`
`XVI. YOU WITH ME?
`A.
`I BELIEVE SO.
`Q.
`ALL RIGHT.
`AND THEN AT THE TOP, THE FIRST LINE OF THE
`ACKNOWLEDGEMENTS, YOU STATE -- NOW, THIS IS A BOOK COPYRIGHTED
`BY NUVASIVE; AM I CORRECT?
`A.
`I BELIEVE SO, YES.
`Q.
`AND YOU HELPED PUT THE BOOK TOGETHER, RIGHT? THAT'S
`WHAT THE SECOND PARAGRAPH OF THE ACKNOWLEDGEMENT STATES.
`A.
`DID I HELP PUT IT TOGETHER?
`Q.
`YES.
`A.
`PHYSICALLY, I DIDN'T. I WAS, I'M PROUD OF THE BOOK;
`BUT TO SUGGEST THAT I WROTE ANYTHING WOULD BE MISLEADING.
`Q.
`RIGHT. BUT I'M JUST REFERRING TO THE SECOND
`PARAGRAPH, SECOND SENTENCE, WHERE IT STATES, "HER WORK ALONG
`WITH THE SUPPORT OF PAT MILES MADE THIS PUBLICATION POSSIBLE."
`DO YOU SEE THAT?
`A.
`YES.
`Q.
`YOU'RE PAT MILES?
`A.
`I AM HE.
`Q.
`OKAY.
`NOW, LET'S GO BACK TO THE TOP OF THE ACKNOWLEDGEMENTS
`PARAGRAPH. IT SAYS, "WE WOULD LIKE TO ACKNOWLEDGE THE WORK OF
`LUIZ PIMENTA WHO REALIZED THE POTENTIAL APPLICATIONS OF
`MINIMALLY INVASIVE LATERAL SURGERY OF THE SPINE."
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`409
`
`
`11
`
`

`
`08-CV-1512-MMA
`
`A.
`Q.
`
`DO YOU SEE THAT?
`YES, SIR.
`OKAY.
`NOW, CAN YOU TURN TO, OH, THE PAGE -- IF YOU LOOK AT
`THE LOWER RIGHT-HAND CORNER OF THESE THINGS, OF THESE PAGES,
`THERE'S AN MNUV NUMBER. DO YOU SEE THAT?
`A.
`I DO.
`Q.
`WE CALL THOSE BATES NUMBERS. AND IF YOU CAN TURN TO
`THE ONE NUMBERED 82166. YOU WITH ME?
`A.
`GETTING THERE. OKAY.
`Q.
`DAVE, CAN YOU BLOW UP THE LAST TWO SENTENCE ON THAT
`PAGE? AND THERE'S A STATEMENT THERE. DO YOU SEE IT?
`IT SAYS, "THE XLIF TECHNIQUE WAS FIRST PRESENTED BY
`LUIZ PIMENTA IN 2001 AS A MINIMALLY INVASIVE PROCEDURE FOR
`INTERBODY FUSIONS ABOVE L5."
`DO SEE THAT?
`I DO.
`A.
`AND DO YOU RECALL THAT SPECIFICALLY WE'RE TALKING
`Q.
`ABOUT MAY OF 2001 WHEN HE PRESENTED IT?
`A.
`I DON'T SPECIFICALLY RECALL WHEN HE PRESENTED IT.
`Q.
`OKAY.
`YOU SEE THAT THERE'S A FOOTNOTE NEXT TO THE 2001?
`25, YEAH.
`A.
`YUP. AND IF YOU GO TO THE PAGE BATES STAMPED
`Q.
`82172 -- GOT IT? SEE THE FOOTNOTES?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`410
`
`
`12
`
`

`
`08-CV-1512-MMA
`
`A.
`Q.
`
`I DO.
`A.
`25?
`Q.
`YUP.
`A.
`"PIMENTA, L, LATERAL ENDOSCOPIC TRANSPSOAS
`Q.
`RETROPERITONEAL APPROACH FOR LUMBAR SPINE SURGERY PRESENTED AT
`THE EIGHTH BRAZILIAN SPINE SOCIETY MEETING, BRAZIL, MAY 2001."
`ALL RIGHT?
`I SEE IT, YES.
`OKAY.
`AND THEN BACK TO THE NOVEMBER PRESS RELEASE, CAN YOU
`PUT THAT BACK UP? CAN YOU BLOW UP THE SECOND TO THE LAST
`PARAGRAPH AGAIN? IT'S NOT THAT ONE. THINK MAYBE THE LAST ONE.
`THERE WE GO. AND IT'S YOUR TESTIMONY THAT THE REFERENCE IN
`THIS PRESS RELEASE TO THE MINIMALLY INVASIVE XLIF EXTREME
`LATERAL INTERBODY FUSION APPROACH TO THE SPINE DEVELOPED BY
`NUVASIVE WAS NOT THE XLIF PROCEDURE THAT IS BEING CREDITED TO
`DR. LUIZ PIMENTA AS OF MAY 2001 IN YOUR TEXTBOOK?
`A.
`I'M TESTIFYING THAT THOSE ARE COMPLETELY INDEPENDENT
`EVENTS.
`Q.
`
`OKAY.
`SO AGAIN, THE MINIMALLY INVASIVE XLIF PROCEDURE
`REFERENCED IN YOUR 2001 PRESS RELEASE HAS NOTHING TO DO WITH
`DR. LUIZ PIMENTA; IS THAT YOUR TESTIMONY?
`A.
`THAT IS MY TESTIMONY.
`Q.
`OKAY.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`411
`
`
`13
`
`

`
`08-CV-1512-MMA
`
`EVEN THOUGH IN THE ACKNOWLEDGEMENT YOU CREDIT DR.
`LUIZ PIMENTA AS HAVING PIONEERED XLIF; AM I CORRECT?
`A.
`THAT IS CORRECT.
`Q.
`NOW, WHAT YOU DID NOT HAVE WHEN YOU LAUNCHED, OR BACK
`IN NOVEMBER 2001, WAS THE COROENT IMPLANT; AM I CORRECT?
`A.
`THAT'S CORRECT.
`Q.
`THE COROENT IMPLANT CAME LATER?
`A.
`THAT'S CORRECT.
`Q.
`AND THE COROENT IMPLANT CAME IN 2003?
`A.
`NOT TO MY RECOLLECTION.
`Q.
`ALL RIGHT.
`AND WHAT YOU DID NOT HAVE IN 2001 WAS MAXCESS; AM I
`
`CORRECT?
`I BELIEVE YOU'RE CORRECT.
`A.
`MAXCESS ALSO CAME LATER, BUT YOU DID HAVE MAXCESS IN
`Q.
`OCTOBER OF 2003?
`A.
`THAT'S CORRECT.
`Q.
`SO WHEN XLIF BECAME SAFE AND REPRODUCIBLE FOR LAUNCH
`IN OCTOBER 2003, YOU HAD COROENT AND YOU HAD MAXCESS;
`CORRECT?
`IT'S CORRECT, BUT IT WASN'T BASED SPECIFICALLY ON
`A.
`HAVING THOSE TWO ELEMENTS.
`Q.
`WELL, WAS THE XLIF 60 NOT SAFE AND REPRODUCIBLE IN
`NOVEMBER 2001?
`A.
`NOT IN THE HANDS OF THE MASSES.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`412
`
`
`14
`
`

`
`08-CV-1512-MMA
`
`Q.
`A.
`Q.
`A.
`Q.
`
`NOT IN THE HANDS OF WHO?
`THE MANY.
`NOT IN THE HANDS OF THE MASSES?
`YES.
`I'M NOT FOLLOWING YOU.
`SO XLIF 60 WAS NOT SAFE AND REPRODUCIBLE IN THE HANDS
`OF THE MASSES?
`A.
`YES.
`Q.
`BUT XLIF -- WHAT WAS IT IN 2003? WHAT WAS THE
`PROCEDURE?
`A.
`XLIF 90.
`Q.
`XLIF 90 WAS SAFE AND REPRODUCIBLE IN THE HANDS OF THE
`MASSES?
`YES.
`A.
`THAT'S JUST BECAUSE OF NEUROVISION?
`Q.
`IT'S BECAUSE OF NEUROVISION AND JUST FUNDAMENTALLY
`A.
`THE REPRODUCIBILITY ASSOCIATED WITH THE APPROACH.
`Q.
`AND YOU'RE NOT GOING TO GIVE COROENT ANY CREDIT?
`A.
`ABOUT BEING SAFE?
`Q.
`THE SUCCESS OF XLIF, MR. MILES, ARE YOU GOING TO GIVE
`THE COROENT IMPLANT -- WHAT'S ACTUALLY INSERTED INTO THE
`PATIENT -- ARE YOU GOING TO GIVE IT ANY CREDIT?
`A.
`IT'S PART OF THE PROCEDURE. ITS AN ELEMENT OF --
`Q.
`I UNDERSTAND.
`THE POINT OF THE PROCEDURE IS TO STICK SOMETHING IN A
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`413
`
`
`15
`
`

`
`08-CV-1512-MMA
`
`PATIENT, RIGHT?
`A.
`NO. THE INTENT OF THE PROCEDURE IS TO RESTORE THE
`HEIGHT OF THE DISC SPACE, RESTORE THE ALIGNMENT OF THE SPINE
`AND FIX A PATIENT.
`Q.
`I UNDERSTAND THAT.
`BUT YOU DO THAT WITH AN IMPLANT, DON'T YOU?
`THE IMPLANT IS A COMPONENT OF THAT, YES.
`IS THERE ANYTHING ELSE THAT YOU PUT IN THE PATIENT?
`IT'S NOT A MATTER OF JUST PUTTING SOMETHING INTO THE
`
`A.
`Q.
`A.
`PATIENT.
`I UNDERSTAND THAT. BUT THE POINT OF THE PROCEDURE IS
`Q.
`TO PUT AN IMPLANT IN THE SPACE SO THAT THE INTERBODY SPACE IS
`ABLE TO HEAL, TO FUSE; CORRECT?
`A.
`AND TO ALIGN --
`Q.
`DO YOU USE NEUROVISION TO ALIGN?
`A.
`NO, BUT IT'S IMPERATIVE; YOU NEED IT TO GET THERE.
`Q.
`DO YOU USE MAXCESS TO ALIGN?
`A.
`YOU NEED IT FOR THE EXPOSURE TO GET THERE.
`Q.
`SURE. BUT WHAT'S ULTIMATELY USED TO ALIGN, AND
`WHAT'S ULTIMATELY USED TO PROVIDE STABILITY? IT'S THE IMPLANT,
`RIGHT?
`IT'S INSTRUMENTS THAT WILL REALIGN THE SPINE, AND
`A.
`THEN YOU PLACE AN IMPLANT TO FIX THE SPINE.
`Q.
`I UNDERSTAND. MY ONLY POINT IS THE POINT OF THE XLIF
`PROCEDURE ISN'T TO STICK AN ENDOSCOPIC INSTRUMENT, THE
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`414
`
`
`16
`
`

`
`08-CV-1512-MMA
`
`RETRACTOR, IN A PATIENT; CORRECT? THAT'S NOT THE POINT OF THE
`PROCEDURE?
`ENDOSCOPIC INSTRUMENT -- ENDOSCOPIC INSTRUMENT HAS
`A.
`NOTHING TO DO WITH THE PROCEDURE ITSELF.
`Q.
`THE POINT OF THE XLIF PROCEDURE IS NOT TO STICK A
`RETRACTOR IN A PATIENT; AM I CORRECT?
`A.
`THE INTENT OF THE XLIF PROCEDURE IS TO RESTORE THE
`HEIGHT, THE ALIGNMENT AND FIX THE SPINE.
`Q.
`THE POINT OF THE XLIF PROCEDURE IS NOT TO STICK A
`RETRACTOR IN A PATIENT; AM I CORRECT?
`A.
`IT'S A CORE ELEMENT TO THE PROCEDURE. WHEN YOU SPEAK
`OF A PROCEDURE, YOU MUST SPEAK NOT ONLY OF THE IMPLANT. THE
`IMPLANT IS JUST A COMPONENT OF IT.
`Q.
`ALL RIGHT.
`SO IT'S YOUR TESTIMONY TO THIS JURY THAT PUTTING THE
`IMPLANT IN THE PATIENT IS JUST A SMALL PART OF THIS PROCEDURE;
`THAT'S NOT THE POINT OF THE PROCEDURE?
`A.
`MY TESTIMONY TO THE JURY IS THAT THE IMPLANT IS THE
`FINAL THING YOU PLACE. WITHOUT GETTING TO THE SPINE SAFELY AND
`REPRODUCIBLY, IT REALLY DOESN'T MATTER. IF YOU HAVE COMPLETE
`DISRUPTION ON THE WAY TO THE SPINE, IT DOESN'T MATTER WHAT YOU
`PUT IN THERE.
`Q.
`LET ME SHIFT GEARS. I'LL COME BACK TO THAT IN A
`LITTLE BIT HERE. I WANT TO GET A COUPLE HOUSEKEEPING THINGS
`OUT OF THE WAY.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`415
`
`
`17
`
`

`
`08-CV-1512-MMA
`
`THE '236 PATENT, YOU'RE FAMILIAR WITH IT,
`MR. MILES?
`A.
`YOU'D HAVE TO SHOW IT TO ME.
`Q.
`YOU'VE NEVER HEARD OF THE '236 PATENT?
`A.
`I'VE HEARD OF THE '236 PATENT. I'VE 38 OR SO
`PATENTS.
`YOU'RE THE PRESIDENT OF THE AMERICAS?
`Q.
`YES, I AM.
`A.
`YOU'RE FAMILIAR WITH THIS LAWSUIT?
`Q.
`YES, I AM.
`A.
`YOU UNDERSTAND THERE'S A PATENT BEING ASSERTED BY
`Q.
`NUVASIVE IN THIS LAWSUIT AGAINST MEDTRONIC SOFAMOR DANEK, USA?
`A.
`I DO.
`Q.
`AND YOU KNOW THAT THE PATENT IS THE '236 PATENT
`RELATING TO NEUROMONITORING; DO YOU NOT?
`A.
`I DO.
`Q.
`I'M SORRY?
`A.
`YES, SIR.
`Q.
`YOU DO?
`A.
`YOU ASKED ME IF I KNEW THE ELEMENTS OF THE PATENT.
`Q.
`I DIDN'T ASK YOU THAT.
`A.
`I MISUNDERSTOOD YOU THEN.
`Q.
`SURE. YOU MISUNDERSTOOD ME. THAT'S ALL RIGHT.
`NOW ON THE '236 PATENT, MR. MILES, IT IS A FACT, IS
`IT NOT, THAT THE METHODS OF THE ISSUED CLAIMS OF THE '236
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`416
`
`
`18
`
`

`
`08-CV-1512-MMA
`
`PATENT WERE NOT PERFORMED BY ANY PERSON USING ANY NUVASIVE
`PRODUCT; IS THAT CORRECT, SIR?
`A.
`CAN YOU PLEASE RESTATE THAT?
`Q.
`SURE.
`IT'S A FACT, IS IT NOT, MR. MILES, THAT THE METHODS
`OF THE ISSUED CLAIMS OF THE '236 PATENT WERE NOT PERFORMED BY
`ANY PERSON USING ANY NUVASIVE PRODUCT; AM I CORRECT?
`A.
`NOT TO MY KNOWLEDGE.
`Q.
`SO I AM CORRECT?
`A.
`TO MY KNOWLEDGE, YOU'RE CORRECT.
`Q.
`ALL RIGHT.
`NOW, YOU UNDERSTAND THAT NUVASIVE IN THE OPENING
`STATEMENT HERE HAS SAID THAT SOFAMOR DANEK COPIES THE NUVASIVE
`NEUROVISION SYSTEM BY INFRINGING THE '236 PATENT?
`A.
`I WASN'T HERE DURING THE OPENING STATEMENTS. SO I'M
`NOT SURE WHAT WAS SAID.
`Q.
`YOU'LL AGREE WITH ME THAT IF NUVASIVE DOESN'T
`PRACTICE THE '236 PATENT, AND SOFAMOR DANEK DOES PRACTICE THE
`'236 PATENT, SOFAMOR DANEK ISN'T COPYING WHAT NUVASIVE IS
`DOING; IS THAT LOGICAL?
`A.
`YEAH, I WOULD LEAVE IT TO YOU GUYS TO FIGURE THAT
`OUT.
`Q.
`
`OKAY.
`NOW NEUROMONITORING IS DESIGNED TO DEAL WITH THE
`PSOAS MUSCLE; AM I CORRECT?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`417
`
`
`19
`
`

`
`08-CV-1512-MMA
`
`YES, GENERALLY.
`A.
`NOW, THE PSOAS MUSCLE IS NOT AN ISSUE ALONG THE
`Q.
`ENTIRE SPINE; AM I CORRECT?
`A.
`IN WHAT CONTEXT?
`Q.
`ANY CONTEXT.
`A.
`IS IT NOT AN ISSUE ALONG THE ENTIRE SPINE?
`Q.
`YES, SIR.
`A.
`I WOULD NEED MORE INFORMATION TO APPRECIATE, YOU
`KNOW, EXACTLY WHAT YOU'RE TALKING ABOUT.
`Q.
`SURE.
`YOU'RE FAMILIAR WITH THE L1-L2 REGION OF THE SPINE?
`YES, I AM.
`THE PSOAS MUSCLE DOESN'T FACTOR INTO THAT REGION,
`
`A.
`Q.
`DOES IT?
`A.
`ELEMENTS?
`Q.
`THERE?
`IT BECOMES -- AS YOU GO UP THE SPINE, ANATOMICALLY,
`A.
`IT'S OF LESS AND LESS -- SHOULDN'T SAY OF LESS AND LESS
`IMPORTANCE. THERE'S LIKELY LESS ANOMALIES IN THE NEURO
`ELEMENTS.
`Q.
`LIKELY LESS ANOMALY IN THE NEURO ELEMENTS?
`A.
`IT MEANS THAT THE LIKELIHOOD OF HAVING NERVES IN THE
`WAY OF A DISC PACE OF L1 IS DIFFERENT THAN HAVING NERVES IN THE
`
`IN WHAT CAPACITY? AS IT RELATES TO THE NEURO
`
`AS IT RELATES TO NEEDING NEUROVISION TO GET THROUGH
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`418
`
`
`20
`
`

`
`08-CV-1512-MMA
`
`WAY OF, SAY, L4-5.
`Q.
`DR. SMITH IS A CONSULTANT WITH THE COMPANY. DO YOU
`KNOW DR. SMITH?
`A.
`I KNOW DR. SMITH.
`Q.
`DR. SMITH SAID, ABOVE THE L3-L4 REGION, YOU CAN DO
`WITH OR WITHOUT NEUROVISION.
`DO YOU AGREE WITH THAT?
`I THINK IF YOU ASKED A LOT OF SURGEONS, YOU'D GET A
`A.
`LOT OF DIFFERENT ANSWERS.
`Q.
`I'M ASKING YOU, DO YOU AGREE WITH YOUR OWN
`CONSULTANT, DR. SMITH, THAT ABOVE THE L3-L4 REGION YOU CAN DO
`WITH OR WITHOUT NEUROVISION; DO YOU AGREE WITH HIM OR DISAGREE
`WITH HIM?
`A.
`I DISAGREE WITH HIM.
`Q.
`YOU DISAGREE WITH HIM?
`A.
`YES.
`Q.
`OKAY.
`DR. FOLEY, HE WAS A CONSULTANT TO YOU ON THE, FOR
`NEUROMONITORING; CORRECT?
`A.
`YES.
`Q.
`DR. FOLEY SAYS THAT THE QUESTION OF WHETHER OR NOT
`YOU NEED NEUROVISION FOR PURPOSES OF DEALING THE PSOAS IS STILL
`AN ISSUE. IT'S AN ISSUE OF DEBATE OUT THERE IN THE MEDICAL
`COMMUNITY. DO YOU AGREE OR DISAGREE WITH DR. FOLEY, YOUR
`CONSULTANT?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`419
`
`
`21
`
`

`
`08-CV-1512-MMA
`
`DR. FOLEY HAS NEVER DONE AN XLIF, TO MY KNOWLEDGE.
`A.
`SO I WOULD DISAGREE WITH HIM. HE DOESN'T HAVE THE EXPERIENCE
`TO, YOU KNOW, HAVE A CREDIBLE COMMENT, IN MY MIND.
`Q.
`SO DR. FOLEY, THE CONSULTANT YOU HIRED FOR PURPOSES
`OF NEUROMONITORING CANNOT OFFER A CREDIBLE OPINION ON THE
`SUBJECT OF THE NEUROMONITORING; THAT'S YOUR TESTIMONY?
`A.
`THAT'S MY TESTIMONY, YES.
`Q.
`I'M SORRY?
`A.
`YES, THAT IS.
`Q.
`THAT IS YOUR TESTIMONY; OKAY.
`IT IS A FACT THAT NUVASIVE SELLS IMPLANTS FOR USE IN
`THE THORACIC AND UPPER LUMBAR; CORRECT?
`A.
`THAT IS CORRECT.
`Q.
`MR. MILES, DO YOU HAVE A POLICY AT NUVASIVE THAT YOU
`WILL NOT SELL YOUR COROENT IMPLANTS UNLESS THE HOSPITAL USES
`YOUR BRAND OF NEUROMONITORING, THE NEUROVISION SYSTEM?
`A.
`WE HAVE A POLICY THAT DOES NOTHING BUT DRIVES THE
`HIGHEST LIKELIHOOD FOR SAFETY AND REPRODUCIBILITY; AND SEEING
`THAT NEUROVISION IS THE ONLY DEVICE THAT HAS BEEN ASSEMBLED TO
`A TECHNIQUE, WE HAVE A POLICY, YES. IT SAYS, NEUROVISION
`SHOULD BE THE ONLY NEUROPHYSIOLOGY USED WITH XLIF.
`Q.
`YOU SAID THAT SEEING THAT NEUROVISION IS THE ONLY
`SYSTEM -- WHAT DID YOU SAY? SOMETHING ASSEMBLED TO THE
`TECHNIQUE?
`A.
`WHAT I'M SAYING IS THAT THROUGH YEARS OF EXPERIENCE
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`420
`
`
`22
`
`

`
`08-CV-1512-MMA
`
`AND THOUSANDS OF CASES WE HAVE VALIDATED THE SAFETY AND
`REPRODUCIBILITY OF NEUROVISION AS A TOOL WITH XLIF. SO WE
`BELIEVE STRONGLY THAT IF THAT IS OUR EXPERIENCE, WE OWE THE
`SURGEON THAT LEVEL OF CONFIDENCE.
`Q.
`SO IF YOU WANT A COROENT, YOU HAVE TO BUY THE
`NEUROVISION EQUIPMENT; IS THAT RIGHT?
`A.
`IT'S BACK TO WHAT I SAID. THE COROENT IS NOT THE MAIN
`ELEMENT OF THE PROCEDURE. IT IS AN ASSEMBLED GROUP OF THINGS
`THAT MAKES THE THING SUCCESSFUL.
`Q.
`THAT'S RIGHT. PEOPLE GET SURGERY TO GET
`NEUROMONITORING; THAT'S WHAT YOU'RE SAYING.
`A.
`IF THAT'S THE CONTEXT THAT YOU'D LIKE TO SAY IT.
`Q.
`YOU'RE TELLING ME THAT PEOPLE DON'T GET THE SURGERY
`TO GET THE IMPLANT?
`A.
`THAT'S NOT TRUE.
`Q.
`THAT'S NOT TRUE. THEY GET THE SURGERY TO GET THE
`IMPLANT?
`A.
`
`WHAT I'M TELLING YOU, AND YOU CAN MAKE A MOCKERY OF
`
`IT --
`
`Q.
`
`I'M NOT MAKING A MOCKERY OF IT, MR. MILES.
`THE COURT: LET ME GET INVOLVED IN THIS NOW. IT
`SEEMS TO ME THAT WE'RE GENERATING INTO AN ARGUMENT HERE. SO
`MAYBE WE CAN DIAL IT BACK A LITTLE BIT AND JUST GET BACK ON A
`QUESTION-AND-ANSWER MOTIF INSTEAD OF PICKING AT EACH OTHER.
`WHAT DO YOU THINK? IS THAT FAIR?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`421
`
`
`23
`
`

`
`08-CV-1512-MMA
`
`MR. DAUCHOT: WILL DO. FAIR ENOUGH.
`BY MR. DAUCHOT:
`Q.
`MR. MILES, YOU GRADUATED FROM COLLEGE IN MACON,
`GEORGIA; AM I RIGHT?
`A.
`YES, SIR.
`Q.
`AND YOU HAVE A DEGREE IN FINANCE?
`A.
`I DO.
`Q.
`AND YOU HAVE NO FURTHER FORMAL EDUCATION AFTER
`THAT?
`NO.
`A.
`AND DID YOU HAVE ANY ADDITIONAL FORMAL -- YOU'RE NOT
`Q.
`A BIOMECHANICAL ENGINEER?
`A.
`NO, SIR.
`Q.
`YOU'RE NOT AN ENGINEER?
`A.
`NO, SIR.
`Q.
`AND YOU'RE NOT A DOCTOR?
`A.
`NO.
`Q.
`BUT YOU ARE THE PERSON THAT YOU MOST RECOLLECT AS
`HAVING DEVELOPED COROENT?
`A.
`YES.
`Q.
`NOW THERE'S BEEN TESTIMONY TODAY THAT, TESTIMONY
`TODAY BY DR. SMITH THAT COROENT WAS VERY INNOVATIVE BY VIRTUE
`OF ITS LENGTH; NAMELY, THAT IT SPANNED THE ENTIRE TRANSVERSE
`WIDTH OF THE VERTEBRAL BODY; DO YOU AGREE WITH HIM?
`A.
`THAT IT WAS INNOVATIVE?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`422
`
`
`24
`
`

`
`08-CV-1512-MMA
`
`YES.
`Q.
`YES.
`A.
`BECAUSE HE SAID IT SPANNED THE ENTIRE WIDTH OF THE
`Q.
`VERTEBRA BECAUSE IT WAS TRANSLATERAL, COAST TO COAST; DO YOU
`AGREE WITH THAT?
`A.
`I THINK THERE'S MANY ELEMENTS THAT MAKE IT
`INNOVATIVE.
`Q.
`MY QUESTION IS: IS IT A FACT DR. SMITH SAID THAT IT
`WAS INNOVATIVE BECAUSE IT SPANNED FROM COAST TO COAST; DO YOU
`AGREE WITH DR. SMITH?
`A.
`I AGREE WITH DR. SMITH THAT IT'S IMPORTANT TO GO ALL
`THE WAY ACROSS A DISC SPACE AND SIT ON THE RING OF APOPHYSIS,
`YES, I DO.
`Q.
`MY QUESTION IS, DR. SMITH SAID IT WAS INNOVATIVE
`BECAUSE IT SPANNED FROM COAST TO COAST AND THAT HE HAD NOT SEEN
`SOMETHING LIKE THAT BEFORE; HE SAID IT WAS INNOVATIVE. MY
`QUESTION IS, DO YOU AGREE WITH DR. SMITH, YOUR CONSULTANT, THAT
`THE COROENT IMPLANT WAS INNOVATIVE BY VIRTUE OF SPANNING FROM
`COAST TO COAST?
`MR. SCHERKENBACH: OBJECTION, YOUR HONOR. IT'S
`ARGUMENTATIVE AND LACKS FOUNDATION.
`THE COURT: OVERRULED. GO AHEAD.
`THE WITNESS: SOLELY, NO. THAT'S NOT THE ONLY
`INNOVATIVE ELEMENT OF THE IMPLANT.
`BY MR. DAUCHOT:
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`423
`
`
`25
`
`

`
`08-CV-1512-MMA
`
`THAT IS NOT THE INNOVATIVE --
`Q.
`THAT IS NOT THE ONLY ELEMENT.
`A.
`IS IT AN INNOVATIVE ELEMENT OF THE IMPLANT? CAN YOU
`Q.
`GIVE US THAT?
`A.
`IS IT AN INNOVATIVE PORTION?
`Q.
`YES, SIR.
`A.
`I BELIEVE SO.
`Q.
`OKAY.
`NOW YOU TAKE CREDIT FOR DEFINING THE REQUIREMENTS FOR
`THE LENGTHS THAT THE COROENT EXCEL COMES IN, DO YOU NOT?
`THAT'S SOMETHING THAT YOU CREDIT TO YOURSELF?
`A.
`YES, SIR.
`Q.
`BUT YOU DON'T REMEMBER WHEN YOU CONCEIVED OF THAT
`IDEA; AM I CORRECT?
`A.
`NOT 11 YEARS AGO I DON'T.
`Q.
`NOW, THE FACT IS THAT IMPLANTS SIZED LIKE COROENT HAD
`BEEN USED IN SURGERIES DURING THE '90S, AM I CORRECT, DURING
`THE 1990'S?
`A.
`NOT TO MY RECOLLECTION.
`Q.
`DO YOU HAVE ANY KNOWLEDGE THAT SOFAMOR DANEK, THE
`COMPANY YOU USED TO WORK FOR, WAS WORKING IN THIS AREA BOTH IN
`THE STATES AND IN EUROPE?
`A.
`IN WHAT AREA?
`Q.
`IN THE AREA OF INTERBODY FUSION AND SELLING THE LONG
`CAGES, THE COAST-TO-COAST CAGES; DO YOU HAVE ANY MEMORY OF
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`424
`
`
`26
`
`

`
`08-CV-1512-MMA
`
`THAT?
`NO MEMORY WHATSOEVER.
`A.
`QUICK QUESTION ON MAXCESS. THE PIVOTING FEATURE OF
`Q.
`THE MAXCESS TWO WAS CARRIED OVER TO THE MAXCESS THREE
`RETRACTOR; AM I CORRECT?
`A.
`YES.
`Q.
`AND THAT WAS DONE, THE PIVOTING FEATURE, WAS MOVED
`FROM MAXCESS TWO TO MAXCESS THREE BECAUSE THERE WAS A FEELING
`AS THOUGH IT WAS A VALUABLE FEATURE SET FOR CERTAIN
`APPLICATIONS; AM I CORRECT?
`A.
`YES.
`Q.
`AND NUVASIVE IS DESIGNING A MAXCESS FOUR RETRACTOR;
`AM I CORRECT?
`A.
`YES.
`Q.
`AND A NEXT GENERATION; IT'S STILL UNDER
`DEVELOPMENT?
`A.
`NO.
`Q.
`IT'S NOT GOING TO BE LAUNCHED?
`A.
`WE'VE ALREADY LAUNCHED IT.
`Q.
`AND WHEN DID YOU LAUNCH IT?
`A.
`A MONTH OR SO AGO.
`Q.
`YOU LAUNCHED IT A MONTH OR SO AGO. AND IT HAS THE
`PIVOTING FEATURE?
`A.
`MAXCESS FOUR HAS THE PIVOTING FEATURE.
`Q.
`I TAKE IT YOU HAVE THE PIVOTING FEATURE IN THERE
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`425
`
`
`27
`
`

`
`08-CV-1512-MMA
`
`BECAUSE YOU SEE IT AS VALUABLE?
`A.
`YES. THE INDEPENDENT PIVOTING OF BLADES IS
`VALUABLE.
`Q.
`AND YOU DON'T CONSIDER IT DANGEROUS, THE PIVOTING OF
`THE BLADES?
`A.
`IT DEPENDS ON HOW YOU USE IT.
`Q.
`ALL RIGHT.
`MR. OJEDA, MARK OJEDA, DO YOU KNOW HIM?
`I DO.
`HE USED TO WORK WITH YOU AT SOFAMOR DANEK; IS THAT
`
`A.
`Q.
`RIGHT?
`A.
`Q.
`CORRECT?
`A.
`Q.
`CORRECT?
`HE DOES.
`A.
`MR. OJEDA -- YOU WERE PERSONALLY INVOLVED AT NUVASIVE
`Q.
`IN THE DEVELOPMENT OF THE HELIX PLATE; AM I CORRECT?
`A.
`AT NUVASIVE, YES.
`Q.
`AND THE HELIX PLATE WAS DEVELOPED, WHAT, IN 2006-ISH,
`'7-ISH?
`A.
`Q.
`
`CORRECT.
`MR. OJEDA REPORTED TO YOU AT SOFAMOR DANEK; AM I
`
`HE DID.
`MR. OJEDA NOW WORKS WITH YOU AT NUVASIVE; AM I
`
`SOMETHING LIKE THAT.
`AFTER MR. OJEDA CAME ON BOARD; CORRECT?
`
`426
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`
`28
`
`

`
`08-CV-1512-MMA
`
`I BELIEVE SO, YES.
`A.
`NOW, THE HELIX PLATE USES A COIL LOCKING MECHANISM;
`Q.
`AM I CORRECT?
`A.
`YES.
`Q.
`IT'S THE ONLY LOCKING MECHANISM THAT YOU CAN RECALL
`NUVASIVE EVER CONSIDERING FOR IT'S HELIX PLATE; AM I CORRECT?
`A.
`IT'S -- THE NAME HELIX CAME AFTER THE DEFINITION OF
`THE LOCKING MECHANISM. SO AS IT RELATES TO -- THE NAME CAME
`AFTER THE LOCKING MECHANISM. SO WE WENT THROUGH MANY LOCKING
`MECHANISMS BEFORE WE EVER GOT TO A HELICAL COIL.
`Q.
`DURING THE DEVELOPMENT OF THE HELIX PLATE, DO YOU
`RECALL ANY OTHER LOCKING MECHANISM THAT NUVASIVE CONSIDERED
`OTHER THAN THE COIL?
`A.
`I DO.
`Q.
`CAN YOU PLEASE RUN CLIP 18?
`(VIDEO WAS PLAYED.)
`"QUESTION: DURING DEVELOPMENT OF THE HELIX PLATE, DO
`YOU RECALL ANY OTHER LOCKING MECHANISM THAT NUVASIVE
`CONSIDERED OTHER THAN THE COIL.
`ANSWER: I REALLY DON'T."
`BY MR. DAUCHOT:
`Q.
`ALL RIGHT.
`MR. MILES, NUVASIVE DECIDED TO USE A COIL BECAUSE IT
`ACCOMMODATED THE ORIGINAL REQUIREMENTS FOR THE HELIX AS DEFINED
`BY MARK OJEDA; AM I CORRECT?
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`427
`
`
`29
`
`

`
`08-CV-1512-MMA
`
`A.
`Q.
`
`CAN YOU PLEASE RESTATE THE QUESTION?
`SURE.
`NUVASIVE DECIDED TO USE THE COIL BECAUSE IT
`ACCOMMODATED THE ORIGINAL REQUIREMENTS FOR THE HELIX AS DEFINED
`BY MARK OJEDA; AM I CORRECT?
`A.
`IT FULFILLED THE DESIGN REQUIREMENTS, THAT'S
`CORRECT.
`MY QUESTION IS, THE DESIGN REQUIREMENTS WERE
`Q.
`ESTABLISHED BY MARK OJEDA, DEFINED BY MARK OJEDA; AM I
`CORRECT?
`YEAH. IT'S TYPICAL THAT THE PERSON WHOSE MOST
`A.
`RESPONSIBLE FOR THE MARKETING OF THE DEVICE RIGHTS THE
`REQUIREMENTS.
`Q.
`AND THAT WAS MARK OJEDA?
`A.
`YES, SIR, IT WAS.
`Q.
`HE CAME UP WITH THE COIL?
`A.
`HE DIDN'T COME UP WITH THE COIL, NO.
`Q.
`HE DEFINED THE COIL AS A REQUIREMENT?
`A.
`NO, HE DIDN'T DEFINE THE COIL AS A REQUIREMENT. HE
`DEFINED THE REQUIREMENT OF A LOCKING MECHANISM.
`Q.
`ALL RIGHT. CAN WE RUN CLIP 19 PLEASE?
`(A DISCUSSION WAS HELD BETWEEN COUNSEL.)
`MR. DAUCHOT: PLEASE RUN CLIP 19.
`(THE VIDEO WAS PLAYED.)
`"QUESTION: DO YOU KNOW WHY NUVASIVE DECIDED TO USE A
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`428
`
`
`30
`
`

`
`08-CV-1512-MMA
`
`COIL.
`
`ANSWER: YES.
`QUESTION: AND WHY IS THAT.
`ANSWER: I BELIEVE IT ACCOMMODATED THE ORIGINAL
`REQUIREMENTS AS DEFINED BY MARK."
`BY MR. DAUCHOT:
`Q.
`AND THAT WAS MARK OJEDA?
`A.
`YES, SIR. HE DEFINED THE REQUIREMENT FOR A LOCKING
`MECHANISM.
`Q.
`FOR THE COIL?
`A.
`HE DIDN'T COME UP WITH THE COIL, BUT HE DEFINED A
`MECHANISM TO MITIGATE SCREW BACK-OUT, AND THAT WAS A NECESSARY
`ELEMENT OF A PLATE.
`Q.
`ALL RIGHT, SIR.
`NOW, I WANT TO COME BACK TO DR. PIMENTA. DO YOU
`AGREE THAT DR. PIMENTA WAS VERY SIGNIFICANT IN TERMS OF
`NUVASIVE'S DEVELOPMENT OF THE XLIF PROCEDURE?
`A.
`DR. PIMENTA WAS KEY IN DEFINING HOW TO GET FROM SKIN,
`FROM THE SKIN TO THE PSOAS MUSCLE ON THE SIDE OF THE SPINE, AND
`I THINK THAT'S SIGNIFICANT.
`Q.
`ALL RIGHT.
`I WANT TO

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket